Inovio Pharmaceuticals (INO) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 0.0% versus a loss of 11.8%. Over five years, LRMR leads with a -69.0% price change compared with -98.0% for INO. Inovio Pharmaceuticals is the larger company by market cap ($329.7 million vs $328.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | LRMR |
|---|---|---|
| Share price | $1.76 | $3.14 |
| Market cap | $329.66M | $328.55M |
| 1-day change | +2.92% | -2.48% |
| YTD return | +1.15% | -17.59% |
| 1-year return | 0.00% | -11.80% |
| 5-year return | -97.98% | -68.97% |
| EPS (TTM) | $-0.59 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $65.34K | — |
| Revenue growth (YoY) | -69.99% | — |
| Net income (latest FY) | $-84.95M | $-165.67M |
| Operating margin | -132871.32% | — |
| Net margin | -130000.00% | — |
| 52-week high | $2.72 | $6.42 |
| 52-week low | $0.56 | $1.92 |
| Distance from 52-week high | -35.29% | -51.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +259.66% | +352.23% |
| Average volume | 11.24M | 1.38M |
| Shares outstanding | 187.31M | 104.63M |
| Employees | 112 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed LRMR by 11.8 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
INO vs LRMR FAQ
Which is bigger, Inovio Pharmaceuticals or Larimar Therapeutics?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $329.66M compared with $328.55M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, INO or LRMR?
INO returned 0.00% over the past 12 months, compared with -11.80% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.